Free Trial
NASDAQ:AXDX

Accelerate Diagnostics (AXDX) Stock Price, News & Analysis

Accelerate Diagnostics logo
$0.04 +0.04 (+∞)
As of 05/14/2025
This is a fair market value price provided by Polygon.io. Learn more.

About Accelerate Diagnostics Stock (NASDAQ:AXDX)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.03
$1.18
52-Week Range
N/A
Volume
53.64 million shs
Average Volume
479,639 shs
Market Capitalization
$857,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
Strong Buy

Company Overview

Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.

Accelerate Diagnostics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
35th Percentile Overall Score

AXDX MarketRank™: 

Accelerate Diagnostics scored higher than 35% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Earnings Growth

    Earnings for Accelerate Diagnostics are expected to grow in the coming year, from ($2.30) to ($2.00) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Accelerate Diagnostics is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    1.94% of the float of Accelerate Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Accelerate Diagnostics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Accelerate Diagnostics has recently increased by 1.57%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Accelerate Diagnostics does not currently pay a dividend.

  • Dividend Growth

    Accelerate Diagnostics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    1.94% of the float of Accelerate Diagnostics has been sold short.
  • Short Interest Ratio / Days to Cover

    Accelerate Diagnostics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Accelerate Diagnostics has recently increased by 1.57%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Accelerate Diagnostics has a news sentiment score of -0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.69 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Accelerate Diagnostics this week, compared to 1 article on an average week.
  • MarketBeat Follows

    2 people have added Accelerate Diagnostics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Accelerate Diagnostics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,885.00 in company stock.

  • Percentage Held by Insiders

    43.60% of the stock of Accelerate Diagnostics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 17.14% of the stock of Accelerate Diagnostics is held by institutions.

  • Read more about Accelerate Diagnostics' insider trading history.
Receive AXDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Accelerate Diagnostics and its competitors with MarketBeat's FREE daily newsletter.

AXDX Stock News Headlines

Think NVDA’s run was epic? You ain’t seen nothin’ yet
Ask most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?
See More Headlines

AXDX Stock Analysis - Frequently Asked Questions

Accelerate Diagnostics, Inc. (NASDAQ:AXDX) issued its quarterly earnings data on Thursday, March, 20th. The medical research company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.50) by $0.13. The medical research company had revenue of $2.82 million for the quarter, compared to analysts' expectations of $3 million.

Accelerate Diagnostics shares reverse split on Wednesday, July 12th 2023. The 1-10 reverse split was announced on Wednesday, July 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Accelerate Diagnostics' top institutional shareholders include Griffin Asset Management Inc. (3.38%) and Simplex Trading LLC. Insiders that own company stock include Jack Phillips, Larry Michael Mertz, David Patience and Steven Reichling.
View institutional ownership trends
.

Shares of AXDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Accelerate Diagnostics investors own include Himax Technologies (HIMX), Sangamo Therapeutics (SGMO), Magnachip Semiconductor (MX), Universal Display (OLED), Energy Transfer (ET), Fluidigm (FLDM) and Netflix (NFLX).

Company Calendar

Last Earnings
3/20/2025
Today
5/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:AXDX
Employees
220
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-61,620,000.00
Net Margins
-471.83%
Pretax Margin
-444.14%

Debt

Sales & Book Value

Annual Sales
$11.70 million
Price / Cash Flow
N/A
Book Value
($1.37) per share
Price / Book
N/A

Miscellaneous

Free Float
14,125,000
Market Cap
$857,000.00
Optionable
Optionable
Beta
0.22

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

This page (NASDAQ:AXDX) was last updated on 5/22/2025 by MarketBeat.com Staff
From Our Partners